


## Contents

-Figure S1. <sup>1</sup>HNMR spectra in MeOD-*d*<sub>4</sub> for the final compounds, rivastigmine-indole hybrids (5a1-3; 5b1-3; 5c1-3)


-Figure S2. <sup>13</sup>CNMR spectra in MeOD-*d*<sub>4</sub> for the final compounds, rivastigmine-indole hybrids (5a1-3; 5b1-3; 5c1-3)

-Figure S3. Redocking results with superimposition of the crystalized ligand a) donepezil (yellow, PDB code 4EY7 [27]) with the best docked pose within hAChE and b) *N*-((1-(2,3-dihydro-1*H*-inden-2-yl)piperidin-3-yl)methyl)-*N*-(2-methoxyethyl)-2-naphthamide (yellow, PDB code 4TPK [28]) with the best docked pose within hBChE.







5a3




5b1




5b2




5b3



5C1




5c2




### 5c3


Figure S1.  $^1\text{H}$ NMR spectra in MeOD- $d_4$  for the final products, rivastigmine-indole hybrids (5a1-a3; 5b1-b3; 5c1-c3)




5a1




5a2




5a3




5b1




5b2




5b3



5c1



5c2



### 5c3

Figure S2.  $^{13}\text{C}$ NMR spectra in  $\text{MeOD-}d_4$  for the final products, rivastigmine-indole hybrids (**5a1-a3**; **5b1-b3**; **5c1-c3**)




Figure S3. Redocking results with superimposition of the crystalized ligand a) donepezil (yellow, PDB code 4EY7 [27]) with the best docked pose within hAChE and b) *N*-((1-(2,3-dihydro-1*H*-inden-2-yl)piperidin-3-yl)methyl)-*N*-(2-methoxyethyl)-2-naphthamide (yellow, PDB code 4TPK [28]) with the best docked pose within hBChE.

Table S1. Goldscore scoring function values obtained for the RIV-IND hybrids by Gold software [31].

<b>5a1</b>	63.37	57.10
<b>5a2</b>	64.46	53.65
<b>5a3</b>	63.41	56.43
<b>5b1</b>	69.36	62.81
<b>5b2</b>	68.08	60.59
<b>5b3</b>	68.63	60.53
<b>5c1</b>	71.28	64.55
<b>5c2</b>	72.82	64.82
<b>5c3</b>	69.21	65.88
Rivastigmine	47.07	44.28